PPT-HIV-HCV Coinfection in the era of effective antiviral therapy

Author : mia | Published Date : 2022-06-07

Mark Sulkowski MD Professor of Medicine Medical Director Viral Hepatitis Center Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "HIV-HCV Coinfection in the era of effect..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

HIV-HCV Coinfection in the era of effective antiviral therapy: Transcript

Mark Sulkowski MD Professor of Medicine Medical Director Viral Hepatitis Center Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading specific causes of death amongst HIVpositive individuals in the DAD study. G. . Ntetskas. , V. . Papastergiou. , L. . Skorda. , A. . Katsili. , E. . Anastasiou. , M. . Stampori. , E. . Asonitis. , F. . Labrianou. , I. . Familias. , I. . Karagiorgi. , M. . Kladas. , S. . Karatapanis. Todd S. Wills, MD. SPNS HCV Treatment Expansion Initiative. Evaluation and Technical Assistance Center. Infectious Disease Specialist. HCV Response Rates in HIV+ and HIV- Patients Treated With . PegIFN. . + Dasabuvir) + RBV in GT1 . TURQUOISE-I. Phase . 2 . Treatment. Naïve and Treatment . Experienced. Wyles. D, et al. 65. th. AASLD. 2014: Abstract . 1939. . . HIV Coinfection. Source: . Wyles. D, et al. 65. Dalya. Basil. Antiviral Chemotherapy . (Prevention and Treatment of Viral Infection). Viruses are a leading cause of disease and death worldwide. Although public health measures and vaccines are the most effective ways to control many viral infections, preventive measures have not succeeded for numerous viral diseases. For some of these diseases, antiviral drugs have been developed.. Cathryn. L. Samples, MD, MPH, AAHIVS. Director, Boston HAPPENS. Boston Children’s Hospital. Presented at: Improving . Care for Substance Use, HIV and HCV in Adolescents: . Effective Approaches to Assessing, Treating, and Engaging . . Case. 47-Year-Old . Man With Asymptomatic HIV Infection. Case (cont). Initial Clinical Presentation. Laboratory Results. HepaScore. ®. A Composite Biomarker Panel for Liver Fibrosis. Hepatic Steatosis in Patients With HIV/HCV Coinfection. Amber Wheeler, MD. WIHS Scientific Meeting. June 30, 2014. Objectives. To discuss:. Background . Aims. Preliminary “rough” data. Future Directions. HIV-infected . persons have increased. odds of . Co-Infection – Florida, . 2014. . STD and Hepatitis Section in collaboration with HIV/AIDS Section – Surveillance Unit . Division of Disease Control and Health Protection. HIV Disease data from 1981 through December . University of Chicago. Chicago, Illinois. Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection. FORMATTED: 05/02/2016. Chicago, Illinois: May 9, 2016. From . AI . Aronsohn. Todd S. Wills, MD. Martha Friedrich, PhD. SPNS Hepatitis C Treatment Expansion Initiative. University of South Florida. The HIV/HCV Disease Burden. Hepatitis C. In U.S., 4 million HCV+ . →. 85% chronic . Singh B, Huang H, Morton DP, Johnson GP, Gutfraind A, Galvani AP, et al. Optimizing Distribution of Pandemic Influenza Antiviral Drugs. Emerg Infect Dis. 2015;21(2):251-258. https://doi.org/10.3201/eid2102.141024. Hansen Dang,. 1,2*. Yee Hui Yeo,. 1*. Satoshi Yasuda,. 3. Chung-Feng Huang,. 4. Etsuko Iio,. 5. Charles Landis,. 6. Dae Won Jun,. 7. Masaru Enomoto,. 8. Eiichi Ogawa,. 9. Pei-. Chien. Tsai,. GT-1. C212 Trial. Phase . 3. Treatment. Naïve and Treatment . Experienced. Dieterich. . D. , et al. . Clin. Infect Dis. 2014;59:1579-87.. HIV Coinfection. Source: . Dieterich. D. , et al. . Clin. Background. Seasonal influenza is estimated to cause approximately 300,000 to 650,000 deaths worldwide annually. Currently, recommended antiviral agents for influenza (. oseltamivir. ) have not been studied in placebo controlled randomised trials to demonstrate survival benefit in hospitalized patients with influenza.

Download Document

Here is the link to download the presentation.
"HIV-HCV Coinfection in the era of effective antiviral therapy"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.